Based on the discovery of this synthetic lethality between BRCA and PARP, numerous PARPi have been developed, including olaparib, rucaparib, niraparib, talazoparib, and veliparib, which are mainly applied in cancer patients with BRCA1/2 mutations [8,9,10,11,42]. Here, BRCA1 is linked to cancer.